Subscribe to Newsletter

Rob Coker Deputy Editor of The Medicine Maker

Following a Bachelor’s degree in English Literature and a Master’s in Creative Writing, I entered the world of publishing as a proofreader, working my way up to editor. The career so far has taken me to some amazing places, and I’m excited to see where I can go with Texere and The Medicine Maker.

Content by Rob Coker:

Business & Regulation Business Practice

Calling Out Misleading Information

| Rob Coker | 2 min read

FDA letter sent to Edenbridge Pharmaceuticals demonstrates the challenges of getting pharma advertising right.

Business & Regulation Standards & Regulation

GSK’s Flovent Strategy Under Federal Scrutiny?

| Rob Coker | 2 min read

US Senator Elizabeth Warren calls for a federal investigation into GSK and its discontinuation of Flovent HFA

Discovery & Development Drug Discovery

Hail to the Hardy Tardigrade

| Rob Coker | 2 min read

Why scientists are looking to the microscopic marvel of the tardigrade for new approaches to cancer treatment.

Discovery & Development Drug Delivery

RIDE: A New Approach to CRISPR Delivery

| Rob Coker | 2 min read

A new study reports targeted CRISPR delivery in retinal and neurological disease models – without viral vectors.

Business & Regulation Standards & Regulation

AMF’s 2026 AMR Strategy, Revealed

| Rob Coker | 3 min read

The Access to Medicine Foundation has developed the 2026 AMR Benchmark to recognize and promote urgency in the ongoing AMR challenge.

Discovery & Development Drug Discovery

Breast Cancer Breakthrough

| Rob Coker

Scientists develop treatment that leads to complete regression of breast tumors in mice.

Discovery & Development Drug Discovery

Venom: The Last Advance

| Rob Coker | 2 min read

How snake venom, genomic data, and deep learning computation methods have combined to bring new advances in drug discovery.

Business & Regulation Standards & Regulation

Trump’s Tariffs

| Rob Coker | 3 min read

US-based pharmaceutical associations fear the supply chain repercussions of tariffs, and offer advice for a more sustainable alternative.

Business & Regulation Standards & Regulation

Settling the PrEP Patent Disputes

| Rob Coker | 2 min read

With US courts consistently ruling in favor of the PrEP drug manufacture, the CDC and DHHS have had no choice but to be humble.

Business & Regulation Standards & Regulation

Regulatory Flexibility in the Event of A Pandemic

| Rob Coker | 3 min read

Summarizing the updated lessons learned by the European Medicines Agency following the COVID-19 pandemic.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register